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biochemical analysis of the underlying bone tissue has provided
important information for treatment of osteoarthritis. In this study, we
determined the potential role of formononetin, a phytoestrogen isolated
from Astragalus membranaceus to alter the expression of metabolic
markers and cytokine production of human normal osteoblasts (Obs)
and osteoarthritis subchondral osteoblasts (OA Obs).
Methods: Human OA Obs and normal Obs were cultured for 3 days,
7 days or 14 days in presence medium only or were treated with various
doses of formononetin. Cells were analyzed for viability by WST-8 assay,
alkaline phosphatase (ALP) activity, osteogenic markers (osteocalcin
(OCN) and type I collagen (Col I)) and cytokines (interleukin-6 (IL-6),
vascular endothelial growth factor (VEGF), bone morphogenic protein-2
(BMP-2)). The level of IL-6, VEGF, BMP-2, OCN and Col I was increased
in OA Obs compared with normal Obs.
Results: Formononetin dose-dependently decreased ALP, IL-6, VEGF,
BMP-2, OCN and Col I in OA Obs, while markedly increased ALP,
VEGF, BMP-2, OCN and Col I in normal Obs. Interestingly, formononetin
markedly increased the expression of VEGF and BMP-2 for 3 days
of culture and signiﬁcantly increased OCN and Col I at 14 days in
human normal Obs. The remodeling effect of formononetin on osteogenic
markers and cytokines of inﬂammatory mediators was more striking in
OA Obs as well.
Conclusions: These results could suggest that formononetin has biphasic
positive effects on normal Obs and OA Obs by modifying their biological
synthetic capacities.
Acknowledgement: This work was supported by the National Research
Foundation of Korea Grant funded by the Korean Government (2010–
0024833).
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OPEN-LABEL, OPEN-ENDED STUDY OF THE SAFETY OF DICLOFENAC
TOPICAL SOLUTION FOR MANAGEMENT OF OSTEOARTHRITIS:
CHARACTERIZATION OF GASTROINTESTINAL ADVERSE EVENTS
C. Argoff1, J. Patrick2, J. Shainhouse3. 1Albany Med. Coll., Albany, NY, USA;
2Covidien, Hazelwood, MO, USA; 3Nuvo Res. Inc., Mississauga, ON, Canada
Purpose: Oral nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
effective for the treatment of osteoarthritis (OA), but their chronic
use is associated with serious gastrointestinal (GI), cardiovascular, and
potentially other systemic adverse events (AEs). Diclofenac topical
solution (TDiclo) has demonstrated efﬁcacy similar to oral diclofenac
(ODiclo) in randomized, double-blind, clinical trials in OA of the knee,
with fewer GI AEs. The incidence of GI AEs occurring with TDiclo in
patients in an ofﬁce setting was analyzed using safety data from a
Canadian compassionate-use treatment program of TDiclo for OA.
Methods: In this multicenter, open-label, open-ended, compassionate-
use, Phase 3 study, patients with physician-diagnosed OA were instructed
to apply 5 drops (small joint, eg, knuckle), 20 drops (medium joint, eg,
wrist), or 40 drops (large joint, eg, knee) of TDiclo to the affected joint
4 times daily in an uncontrolled, real-world setting. Follow-up safety
assessments were scheduled at 1, 3, 6, and 12 months, and yearly
thereafter. At each visit, patients were asked open-ended questions
regarding the onset and nature of any AE that occurred since the last
visit. It was at the patient’s discretion whether to contact the investigator
at the onset of an AE or wait until the next visit.
Results: A total of 4213 patients were evaluated. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in 19.8%.
A GI AE occurred in 35 (0.8%) patients; the most frequently reported were
dyspepsia (0.4%), nausea (0.2%), and diarrhea (0.1%). A GI AE was listed
as a reason for study discontinuation in 23 patients (0.5%). None of the
GI AEs that occurred during the study were deemed by the investigator
to be related to TDiclo treatment.
Conclusions: In an uncontrolled ofﬁce-practice setting, the occurrence
of GI AEs in patients receiving TDiclo was low. No individual GI AE was
reported in >0.4% of patients, and few patients discontinued therapy
because of these events. The results of this open-label study demonstrate
that TDiclo is a well-tolerated therapeutic option for those patients who
wish to reduce their likelihood of experiencing the GI AEs that are
commonly associated with oral NSAIDs.
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OPEN-LABEL, OPEN-ENDED STUDY OF THE SAFETY OF DICLOFENAC
TOPICAL SOLUTION FOR MANAGEMENT OF OSTEOARTHRITIS:
CHARACTERIZATION OF APPLICATION-SITE ADVERSE EVENTS
J. Shainhouse1, J. Patrick2, C. Argoff3. 1Nuvo Res. Inc., Mississauga, ON,
Canada; 2Covidien, Hazelwood, MO, USA; 3Albany Med. Coll., Albany, NY,
USA
Purpose: Randomized, double-blind trials of diclofenac topical solution
(TDiclo) in osteoarthritis (OA) of the knee have demonstrated efﬁcacy
similar to oral diclofenac, with fewer systemic adverse events (AEs). The
most common AEs occurring with TDiclo were application-site reactions.
To characterize these reactions in a clinical setting, safety data were
analyzed in patients who received TDiclo in a Canadian compassionate-
use treatment program for OA.
Methods: This was a multicenter, open-label, open-ended study
conducted in Canada. Patients with physician-diagnosed OA were
instructed to apply 5 drops (small joint, eg, knuckle), 20 drops (medium
joint, eg, wrist), or 40 drops (large joint, eg, knee) of TDiclo, 4 times
daily. Follow-up safety assessments were scheduled at 1, 3, 6, and
12 months, and yearly thereafter. At each visit, the investigator asked
the patient open-ended questions about any AE occurring since the
last visit, assessed the application site for signs of irritation and scored
it (0 = no visible reaction; 0.5 = equivocal response, itching burning
sensation, pruritus; 1 = mild erythema; 2 = intense erythema; 3 = intense
erythema with edema; and 4 = intense erythema with edema and
vesicular eruption).
Results: A total of 4213 patients were enrolled. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in
19.8%. The most common AEs were application-site reactions in 112
of the 4213 patients (2.7%), which included rash (1.2%), dry skin (0.6%),
and pruritus (0.5%). Data regarding skin irritation score were available
for 1923 patients; of these, 1798 (93.5%) had a score of 0 (no visible
reaction), 59 (3.1%) had a score of 0.5 (equivocal response, itching,
burning sensation); and 48 (2.5%) had a score of 1 (mild erythema).
A score of 2 (intense erythema) was recorded in 7 (0.4%) and a score
of 3 (intense erythema with edema) in 6 (0.3%) patients; a score of 4
(intense erythema with edema and vesicular eruption) was recorded in
only 5 patients (0.3%). A total of 40 patients (0.9%) reported discontinuing
treatment because of an application-site reaction. No data were collected
on potential patient interventions such as emollients or creams.
Conclusions: Consistent with published controlled, clinical trials, the
most common AEs in individuals with OA treated with TDiclo in clinical
practice were skin-related. Their occurrence was low, and few patients
discontinued treatment because of these reactions. Given the risk of
systemic AEs associated with oral diclofenac, TDiclo has obvious potential
for the reduction of adverse effects.
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SCREENING OF ESSENTIAL OILS AS POTENTIAL SOURCES OF NATURAL
INHIBITORS OF iNOS EXPRESSION AND NO PRODUCTION IN HUMAN
CHONDROCYTES
A.T. Ruﬁno1,2, F. Judas3, L. Salgueiro4, M.C. Lopes1,2, C. Cavaleiro4,
A.F. Mendes1,2. 1Ctr. for NeuroSci. and Cell Biology, Coimbra, Portugal;
2Faculty of Pharmacy, Univ. of Coimbra, Coimbra, Portugal; 3Univ. Hosp. of
Coimbra and Faculty of Med., Univ. of Coimbra, Coimbra, Portugal; 4Faculty
of Pharmacy / CEF, Univ. of Coimbra, Coimbra, Portugal
Purpose: Nitric oxide (NO), namely resulting from the activity of the
inducible nitric oxide synthase (iNOS) whose expression is increased
in osteoarthritic chondrocytes, is an important component of the
mechanisms that lead to cartilage degradation and inﬂammation,
the hallmarks of OA. Overexpression of iNOS and the subsequent
increased production of NO mediates, at least in part, the inhibition
of matrix synthesis and promotion of its degradation induced by pro-
inﬂammatory and catabolic cytokines, like interleukin-1b (IL-1), in
articular chondrocytes. Thus, inhibition of NO production and iNOS
expression are considered important targets for the development of anti-
osteoarthritic therapies. Essential oils are composed of a wide diversity
of hydrophobic low molecular weight compounds with favorable
pharmacokinetic properties that make them especially suited collections
for drug screening. Here we report results on a screening of the ability
of ﬁve essential oils to inhibit IL-1-induced iNOS expression and NO
production in human chondrocytes.
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Methods: Cartilage samples were obtained from multi-organ donors
at the University Hospital of Coimbra with approval by the Ethics
Committee. After enzimatic digestion, isolated chondrocytes were
cultured under non proliferating conditions to avoid dedifferentiation.
Essential oils prepared by distillation of the aerial parts of Lavandula
luisieri, Otanthus maritimus, Laserpitium elasii, Annona muricata and
Eryngium duriae subsp. juresianum were added to the chondrocyte
cultures, in at least 3 different concentrations, ranging from 0.0005
to 0.005% (v/v), 30 min before addition of IL-1, 10ng/mL and further
incubated for 18 h. The MTT reduction assay was used to rule out
cytotoxic effects. NO levels were measured by a colorimetric method
based on the Griess reaction. iNOS levels were evaluated by western
blot.
Results: Of the essential oils tested, 2 showed a signiﬁcant ability
to decrease IL-1-induced NO production and iNOS protein levels. L.
luisieri promoted the greatest inhibition (49.9±5.7%) in a concentration
of 0.005% (v/v). A concentration 5x lower, 0.0025%, still promoted a
signiﬁcant decrease (30.0±3.1%) of NO levels. Similarly, the essential
oil from E. duriae subsp. juresianum in concentrations of 0.0025% and
0.001% (v/v) decreased NO production by 38.8±12.8% and 24.6±3.7%,
respectively %. Both oils signiﬁcantly reduced iNOS levels. The effects
observed were achieved with concentrations that did not induce
cytotoxicity.
Conclusions: Among the essential oils screened, those from L. luisieri
and E. duriae subsp. juresianum are promising samples for further
fractionation in order to purify and identify the active component(s).
Future studies will be designed to fully characterize the mechanism of
action of such compound(s) and determine their potential usefulness as
anti-osteoarthritic agents.
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EVIDENCE-BASED RECOMMENDATIONS ON DULOXETINE TREATMENT
FOR THE PAIN IN KNEE AND HIP OSTEOARTHRITIS: SYSTEMATIC
REVIEW AND EXPERT CONSENSUS
L. Teran Estrada1, S.M. Carrillo Vazquez1, A. Rizzoli2, G. Espinosa
Cuervo1, G.I. Holguin Dorador1, A. Perez Perez1, S.M. Lopez Lopez1,
A.A. Paz Viscarra1, A. Campana Parra1, J.M. Miranda Limon1, O.L. Rillo3,
M.V. Goycochea Robles1. 1Mexican Coll. of Rheumatology, Mexico City,
Mexico; 2Res. Unit Hosp Infantil de Mexico, Mexico City, Mexico; 3Sociedad
Argentina de Reumatolog´ıa, Buenos Aires, Argentina
Background: Pain is a major problem concerning patients with
Osteoarthritis (OA). Duloxetine has shown to be effective as a central
acting analgesic in chronic back pain, ﬁbromyalgia and other rheumatic
conditions
Purpose: The aim of this study was to develop evidence-based
recommendations for the use of Duloxetine in the pain of patients with
OA of hip or knee.
Methods: A scientiﬁc committee from the Mexican College of
Rheumatology (CMR) selected clinically relevant questions concerning
the use of Duloxetine in OA. A systematic review of the literature for
randomized controlled trials (RCT) with Duloxetine as treatment for the
pain management in patients with OA was performed blinded by two
experts in systematic review.
Research strategy: We searched RCT using Duloxetine OA in
Medline/PubMed, EMBASE, ARTEMISA, LILACS and the Cochrane Library
in English or Spanish languages.
Selection Criteria: We included RCT, in which adults with knee and or
hip OA were treated with Duloxetine, considering as efﬁcacy outcome
variables: pain and or functional capacity, and safety: adverse events.
Quality of the articles was evaluated by ten experts with the Jadad
Score and CONSORT guidelines 2010. The level of evidence was appraised
according to the Oxford Levels of Evidence. An expert consensus meeting
took place in April 2011 including 12 rheumatologists when the scores
of Jadad and Consort evaluations were revised. Recommendations were
made during interactive workshops where the evidence was reviewed.
Agreement among participants and the impact of the recommendations
were systematically assessed using voting procedure in a plenary
session.
Results: A total of 12 references were identiﬁed, among which nine
were excluded because the intervention evaluated other conditions and
or consider animal models; two articles were included for efﬁcacy and
one for safety. There was a good quality of evidence in the three
articles assessed, in two rounds of discussion between experts. The
recommendations were formulated, including usefulness, population,
optimal dosage and safety. For efﬁcacy Duloxetine was evaluated by
experts as useful considering those patients with persistence intensive
pain (visual analogue scale >4), and with previous use of other analgesics,
without correlation with the disease stage (clinical and radiologic) The
secondary adverse events where reported correctly in the RCT and a safe
proﬁle was identiﬁed by consensus, looking more events with high dose,
but resolved with a scaling dosage administration: starting at 30mg the
ﬁrst week, and then increase at 60mg
Conclusions: Duloxetine is an effective and safety option for the
management of pain in OA of hip and knee in patients with history
of analgesics or NSAIDS and persistency of pain (more than 4 in VAS),
independently of the radiologic stage, at a starting dose of 30mg for
one week an after 60mgd, ingested with food. These recommendations
are evidence based and supported by a panel of the Mexican College of
Rheumatology specialists and experts. Further research has to be place
to evaluate the real cost-effectiveness of Duloxetine in the management
of pain in OA patients.
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A COMPARISON OF ANTI-INFLAMMATORY PROPERTIES OF WHOLE
BLOOD, PLATELET-RICH PLASMA, AND AN AUTOLOGOUS PROTEIN
SOLUTION IN IL-1b- AND TNFa-STIMULATED CHONDROCYTES
A.M. Matuska, K.M. O’Shaughnessey, J.E. Woodell-May. Biomet, Inc.,
Warsaw, IN, USA
Purpose: Autologous intra-articular injections of platelet-rich plasma
(PRP) have been investigated as a potential treatment for cartilage
degeneration. Degradation of the cartilage matrix, seen in early stage
osteoarthritis (OA), is believed to be driven by inﬂammatory cytokines
such as IL-1 and TNFa. These cytokines induce cells in the joint to produce
matrix metalloproteinases (MMPs) that in turn are responsible for
degradation of the cartilage matrix. An autologous protein solution (APS),
which is derived from PRP and contains anti-inﬂammatory cytokines,
has been developed. The purpose of this study was to determine if APS
can inhibit the production of MMP-13 from IL-1b- and TNFa-stimulated
chondrocytes more effectively than PRP.
Methods: Preparation of samples: Nine ml of PRP was prepared from 90ml
fresh whole blood (8.3% v/v ACD-A) using two disposable separation
devices containing a tuned density buoy (Biomet Biologics). Six ml of the
combined PRP output was transferred to a disposable device containing
polyacrylamide beads. The device was centrifuged and the APS was
collected. Cells in the whole blood (WB), remaining PRP, and APS were
lysed by processing 500ml of each sample at 5°C with protease inhibitor
and cell disruption glass beads in a cell disrupter (Scientiﬁc Industries).
The samples were centrifuged at 5°C for 20 minutes at 13,000 rpm
(11,500 g), and the lysate was removed and stored (−50°C) until use in
the assay.
Cell Assay: Human knee articular chondrocytes (NHAC, P5, Lonza Inc.)
were seeded in 12-well plates at 20,000 cells/cm2 in 2ml growth media
(Lonza). Two hours prior to the assay, media was exchanged with serum-
free. The treatment wells were pre-incubated with 25ml WB, PRP, or
APS in a transwell insert (Corning Inc.) for 2 hours before addition of
recombinant IL-1b (5 ng/ml) (Sigma) and TNFa (100ng/ml) (Prospec).
Negative control was untreated media, and positive control contained
only IL-1b (5 ng/ml) and TNFa (100ng/ml). Following incubation at 37°C
and 5% CO2 for 24 hours, the supernatant was removed and frozen
at −50°C. Cells were trypsinized and counted. The supernatant was
assayed for MMP-13 by ELISA (R&D Systems), and MMP-13 production
was normalized to cell number.
Statistical Analysis: A single-factor ANOVA with a post-hoc Fisher LSD
test (a = 0.05) was performed to determine statistically signiﬁcant
differences.
Results: APS was more capable of inhibiting MMP-13 production by
IL-1b- and TNFa-stimulated chondrocytes than an equal dose of WB
(p < 0.0001) or PRP (p =0.0003). WB had no effect on MMP-13 production
compared to the positive control (p = 0.4). PRP and APS inhibited
approximately 45% and 70% of MMP-13 production, respectively.
